Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$593M |
| 2 |
Abbott
ABT
|
+$259M |
| 3 |
AutoZone
AZO
|
+$204M |
| 4 |
AABA
Altaba Inc
AABA
|
+$186M |
| 5 |
D.R. Horton
DHI
|
+$178M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$215M |
| 2 |
Public Service Enterprise Group
PEG
|
+$211M |
| 3 |
Applied Materials
AMAT
|
+$203M |
| 4 |
Intuitive Surgical
ISRG
|
+$194M |
| 5 |
ConocoPhillips
COP
|
+$192M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.49% |
| 2 | Technology | 12.13% |
| 3 | Healthcare | 11.89% |
| 4 | Consumer Discretionary | 11.58% |
| 5 | Industrials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
CALL
Edwards Lifesciences
EW
$52.3B
| $1.13M | ﹤0.01% |
30,000
-120,000
| -80% | -$4.4M |
|
2627
iShares Biotechnology ETF
IBB
$10.8B
| $1.13M | ﹤0.01% |
+10,559
| New | +$1.13M |
|
|
AKTX
2628
Akari Therapeutics
AKTX
$17.7M
| $1.13M | ﹤0.01% |
325
+181
| +126% | +$698K |
|
2629
Calix
CALX
$2.42B
| $1.12M | ﹤0.01% |
188,987
+168,917
| +842% | +$1.02M |
|
|
GES
2630
DELISTED
Guess Inc
GES
| $1.12M | ﹤0.01% |
+66,567
| New | +$1.1M |
|
|
CBM
2631
DELISTED
Cambrex Corporation
CBM
| $1.12M | ﹤0.01% |
23,407
-493,900
| -95% | -$24.5M |
|
2632
Children's Place
PLCE
$59.4M
| $1.12M | ﹤0.01% |
7,728
-36,966
| -83% | -$4.5M |
|
2633
PUT
iRhythm Holdings
IRTC
$3.93B
| $1.12M | ﹤0.01% |
20,000
+10,000
| +100% | +$523K |
|
2634
Strategic Education
STRA
$1.89B
| $1.12M | ﹤0.01% |
12,489
+9,191
| +279% | +$849K |
|
2635
BCB Bancorp
BCBP
$157M
| $1.11M | ﹤0.01% |
76,882
+50,889
| +196% | +$731K |
|
|
EGRX
2636
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $1.11M | ﹤0.01% |
+20,841
| New | +$1.16M |
|
2637
PUT
Align Technology
ALGN
$11.3B
| $1.11M | ﹤0.01% |
5,000
-40,000
| -89% | -$9.09M |
|
2638
Summit Therapeutics
SMMT
$11.4B
| $1.11M | ﹤0.01% |
99,873
+22,759
| +30% | +$254K |
|
|
AVXS
2639
PUT
DELISTED
AveXis, Inc. Common Stock
AVXS
| $1.11M | ﹤0.01% |
+10,000
| New | +$1M |
|
|
CWBC
2640
Community West Bancshares
CWBC
$706M
| $1.1M | ﹤0.01% |
54,495
+14,484
| +36% | +$296K |
|
2641
Verastem
VSTM
$669M
| $1.1M | ﹤0.01% |
29,801
+14,347
| +93% | +$648K |
|
|
AKRX
2642
DELISTED
Akorn Inc
AKRX
| $1.1M | ﹤0.01% |
+34,080
| New | +$1.12M |
|
|
CO
2643
DELISTED
Global Cord Blood Corporation
CO
| $1.1M | ﹤0.01% |
110,375
-14,156
| -11% | -$155K |
|
2644
BioLife Solutions
BLFS
$1.81B
| $1.09M | ﹤0.01% |
182,550
+164,324
| +902% | +$947K |
|
2645
PUT
Illumina
ILMN
$34B
| $1.09M | ﹤0.01% |
5,140
| – | – |
|
2646
Ooma
OOMA
$564M
| $1.09M | ﹤0.01% |
91,193
+54,019
| +145% | +$575K |
|
2647
Westwood Holdings Group
WHG
$189M
| $1.09M | ﹤0.01% |
16,426
+8,626
| +111% | +$573K |
|
2648
Vitamin Cottage Natural Grocers
NGVC
$642M
| $1.09M | ﹤0.01% |
+121,713
| New | +$801K |
|
2649
Zumiez
ZUMZ
$311M
| $1.08M | ﹤0.01% |
52,040
-4,365
| -8% | -$83.5K |
|
2650
Invesco Senior Loan ETF
BKLN
$6.78B
| $1.08M | ﹤0.01% |
46,929
-275,481
| -85% | -$6.36M |
|
Similar funds
Israel Englander's Q4 2017 Portfolio in Review
As of Q4 2017, Israel Englander held 4,357 positions worth $72.5B, up 10% from $65.6B the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.
Israel Englander deployed $3.05B of net new capital in Q4 2017, opening 897 new positions and adding to 1,473 existing holdings. Its largest new stake was Viatris: 2,905,317 shares worth $123M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 14% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Honeywell, an estimated $215M trimmed.
- Israel Englander's largest Q4 2017 buy was Viatris: 2,905,317 shares worth $123M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $593M increase.
- Israel Englander's biggest Q4 2017 reduction was Honeywell, cutting an estimated $215M.
- Israel Englander fully exited Paychex in Q4 2017, selling an estimated $66.4M.
- Israel Englander's ten largest holdings make up 6.7% of its $72.5B portfolio in Q4 2017.
- Israel Englander opened 897 new positions and closed 601 in Q4 2017.
- Israel Englander's portfolio value rose 10% quarter-over-quarter to $72.5B.
Based on Millennium Management's 13F filing for Q4 2017, filed 14 Feb 2018.